Therapeutic Confirmatory (Phase III)

3,259 trials 1,319 recruiting

Filter these 3,259 trials by condition, country, sponsor and more.

Open in Search →

An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended

2024-515185-13-00 geographic atrophy 2022-12-21
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Resected squamous cell carcinoma of the head and neck 2022-12-16
Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep… Ended

2024-513230-38-00 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, 2022-12-15
Randomised placebo controlled clinical trial of efficacy of MYOcardial protection in postacute inFLAMmatory cardiac involvEment due to COVID… Ended

2024-516463-84-00 Inflammatory cardiovascular involvement due to COVID-19 2022-12-13
Multicentre, Phase 3 Trial to Determine Diagnostic Value of 68Ga-PSMA-11 (in PET/CT and PET/MRI) in Intermediate and High-Risk Prostate Canc… Ended

2024-516556-17-00 Intermediate and high-risk prostate cancer 2022-12-12
A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus Ended

2022-500445-24-00 Moderately to Severely Active Systemic Lupus Erythemato 2022-11-30
Phase 3 Study of Tinlarebant in the Treatment in Adolescent Stargardt Subjects Ended

2024-513483-26-00 Stargardt Disease 2022-11-28
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 2022-11-24
Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombo… Ended

2024-513262-19-00 Thrombotic Thrombocytopenic Purpura 2022-11-21
Safety and Immunogenicity of V116 in Adults 50 Years of Age or Older Ended

2022-503144-40-00 Pneumococcal disease 2022-11-17
A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema. Ended

2023-505904-41-00 Hereditary Angioedema Type I or II 2022-11-17
Safety and efficacy of PC945 (opelconazole) in combination with other antifungal therapy for the treatment of refractory invasive pulmonary … Ended

2024-511281-36-00 Refractory Invasive Pulmonary Aspergillosis 2022-11-17
VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended

2022-500079-30-00 IgA Nephropathy 2022-11-03
A study to test trimodulin in adult hospitalized patients with CAP including COVID-19 pneumonia. Ended

2024-513002-60-00 Non-severe community-acquired pneumonia (CAP) or modera 2022-10-26
Impact of dapagliflozin on vascular function in chronic kidney disease patients - (DAPA-VASC) Ended

2024-514887-14-00 chronic kidney disease patients 2022-10-18
A clinical study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with… Ended

2023-503420-19-00 Pediatric lower limb (LL) spasticity (SP) caused by cer 2022-10-12
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended

2024-512803-37-00 Progressive Fibrosing Interstitial Lung Diseases (PF-IL 2022-10-05
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Schizophrenia 2022-09-30
A Phase 3 study to determine the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy (REACH) Ended

2024-512737-33-00 Facioscapulohumeral Muscular Dystrophy (FSHD) 2022-09-30
A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication… Ended

2024-516064-28-00 Acute Graft Versus Host Disease 2022-09-27
A Phase 3 safety study of BAY 94-9027 in children 7 to <12 years of age with severe hemophilia A Ended

2023-504388-18-00 Severe hemophilia A (<1% FVIII:C) 2022-09-26
Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended

2024-512856-40-00 Giant Cell Arteritis 2022-09-21
Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and … Ended

2024-514788-24-00 Chronic stable plaque psoriasis 2022-09-20
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 2022-09-13